EXHIBITOR SPOTLIGHT THEATER PRESENTATIONS

The Exhibitor Spotlight Theaters have been reserved by exhibitors to present new data, conduct promotional meetings or highlight a new service. Exhibitors will be presenting one-hour sessions during the AACR Annual Meeting 2021.

SCHEDULE	
Date/Time (EDT)	**Company**
Saturday, April 10	
9:00 - 10:00 am	Daiichi Sankyo
11:00 am - 12:00 pm	Amgen
1:00 pm - 2:00 pm	Bristol Myers Squibb
3:00 pm - 4:00 pm	Natera
Sunday, April 11	
11:00 am - 12:00 pm	Pfizer Oncology
1:00 pm - 2:00 pm	NanoString
3:00 pm – 4:00 pm	GenScript
Monday, April 12	
11:00 am – 12:00 pm	Miltenyi Biotec B.V. & Co. KG
1:00 pm - 2:00 pm	Bio-Techne
3:00 pm - 4:00 pm	Genmab
Tuesday, April 13	
11:00 am – 12:00 pm	NanoString
1:00 pm - 2:00 pm	BD Biosciences
3:00 pm - 4:00 pm	10x Genomics
Wednesday, April 14	
11:00 am – 12:00 pm	AstraZeneca
1:00 pm - 2:00 pm	Bionano Genomics
3:00 pm - 4:00 pm	Adaptive Biotechnologies
Thursday, April 15	
11:00 am – 12:00 pm	Visiopharm
1:00 pm - 2:00 pm	PerkinElmer

Saturday, April 10, 2021

9:00 a.m.

Daiichi Sankyo

Updates on the Treatment of Patients with Unresectable or Metastatic HER2+ Breast Cancer who Previously Received Anti-HER2 Therapies

Please join Daiichi Sankyo, Inc. and AstraZeneca on Thursday April 10th at 9AM EST for an expert-led discussion to explore updates on the treatment of certain patients with unresectable or metastatic HER2+ breast cancer (mBC). This program, intended for US healthcare professionals, provide attendees with a deeper understanding of a treatment option which addresses a key unmet need for previously treated HER2+ mBC. This session will not only cover the unmet needs of HER2+ mBC patients who have received prior therapies, but provide an overview of the efficacy, key safety considerations, and management of this treatment option.

Speaker: Mohammad Jahanzeb

11:00 a.m.

Amgen

KRAS G12C – A Key Emerging Biomarker in the Pathologic Evaluation of NSCLC

The KRAS G12C mutation occurs in ~13% of patients with Non-Small Cell Lung Cancer, which is comparable to the prevalence of EGFR mutations. Join us to learn about the rapidly evolving landscape of biomarkers in NSCLC, KRAS G12C as a key oncogenic driver and an important biomarker in NSCLC, currently available testing methodologies for the KRAS G12C mutation, clinical guidelines recommendations for testing, and potential strategies for optimizing the biomarker testing journey.

Speaker: Pranil Chandra

1:00 p.m.

Bristol Myers Squibb

Dual I-O Treatment Option for 1L NSCLC

Advanced non-small cell lung cancer has proven to be a difficult disease to treat; however, over the past few years, there have been numerous approvals leading to a multitude of treatment options for physicians to treat 1L NSCLC patients. In this presentation, Dr Rathore will review a hypothetical patient case for appropriate patient selection and discuss I-O clinical trial data.

Speaker: Ritesh Rathore

3:30 p.m.

Natera

Informed by the tumor: the power of a personalized ctDNA assay for MRD detection and monitoring

Highly sensitive and specific ctDNA detection for solid tumors is a prerequisite for applications of ctDNA testing in clinical trial design and in guiding treatment decisions. Join Natera to learn how researchers and clinicians can use Signatera, a personalized, tumor-informed ctDNA assay, to accelerate clinical trial readout and to aid in therapeutic decision-making by detecting molecular residual disease (MRD) and monitoring for treatment response and recurrence across tumor types and treatment settings.

Topics for this discussion include:

Regulatory approval process and global commercialization of a tumor-informed assay Incorporating Signatera in clinical trials Clinical utility of Signatera in early-stage CRC and in immunotherapy monitoring

Moderator: Alexey Aleshin

Speakers: Angel Rodriguez; Andrew Hadd

Sunday, April 11, 2021

11:00 a.m.

Pfizer Oncology

Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials

Pfizer has a long-standing commitment to patient centricity. We prioritize putting the patient's voice at the forefront of all initiatives. This session discusses Pfizer Oncology's Patient Centricity Ecosystem and our dynamic approach to engage advocacy leaders. This approach helps us share how we are engaging patients in clinical trials, addressing health literacy and actively working to solve for inequities in our healthcare system. The session also highlights the work two of our advocacy partners are doing in clinical trials

Speakers: Marianne Gandee; Patti Jewell; Sundiep Phanse; Sue Hensley

1:00 p.m.

NanoString

True Spatial genomics: Measuring the transcriptome in regions, cell and sub-cellular compartments

Spatial Biology is expanding rapidly across various applications with multiple technologies enabling whole transcriptome analysis with multicellular to single cell and subcellular resolution. With GeoMx® Digital Spatial Profiler (DSP) and the newly unveiled Spatial Molecular Imager (SMI), NanoString offers two complementary systems to address all Spatial Biology applications. GeoMx DSP enables whole transcriptome and 100+-plex protein profiling with biology driven multi-cellular spatial resolution. SMI enables highly sensitive analysis of hundreds to thousands of RNAs or proteins within a single cell and sub-cellular resolution in multiple sample types, including formalin-fixed paraffin-embedded.
For Research Use Only. Not for use in diagnostic procedures.

Speaker: **Joseph Beechem**

3:00 p.m.

GenScript

- Characterization of a PARP inhibitor biomarker for cancer therapy

A new generation of drugs have been developed that target the DNA repair enzyme PARP to induce DNA damage and cell death. PARP inhibitor therapy works on the fundamentals of synthetic lethality, where cells with defective homologous recombination repair, as seen in many cancers, are unable to repair PARP inhibitor induced lesions induced. Our data demonstrates a new protein that functions in the repair of DNA damage, could be used as a companion diagnostic for PARP inhibitors. Our priority is to identify the cancer patients most likely to benefit from PARP inhibitor therapy, thereby personalising patient care and improving survival.

Speaker: Joshua Burgess

- Precise and Efficient Non-viral CRISPR Gene Editing Solutions

With the 4th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment. The delivery of specifically designed CAR or T CR encoding component can be done by viral vectors, but with limitations like random insertions and complicated manufacture process. With the power of CRISPR, precise and efficient T cell engineering can be carried out in a non-viral, plasmid-free manner. At this talk, we will show how GenScript can efficiently manufacture sgRNA and DNA payloads for precise CAR/TCR KI in T cells. With this upgraded capability and recent advances in non-viral delivery, efficiently and precisely engineer T cells with minimal off-targets is becoming a reality.

Speaker: Lumeng Ye

Monday, April 12, 2021

11:00 a.m.

Miltenyi Biotec B.V. & Co. KG

Understand tumor complexity – deep phenotyping at single-cell level

- Discover immuno-oncology biomarkers with single-cell genomics

Defining the heterogeneity and states of intratumoral lymphocytes is crucial to improve cancer immunotherapy. We have used scRNA-seq to characterize tumor-infiltrating immune cells within human ovarian cancer. Our study focused on a subset of CD8 cells expressing CD39, a marker associated with tumor antigen reactivity.

Speaker: Mayra Carneiro

- Immunological profiling of cancer by ultrahigh-content imaging

A comprehensive understanding of the TME is indispensable for "evidence-based" combinatorial immunotherapies and next-generation CAR-T engineering. We used the MACSima™ Imaging Platform for multidimensional analysis of a diagnostic 100-marker panel of clinical specimens and started to integrate the system in our pre-clinical research workflow to study CAR-T – Tumor/TME interaction.

Speaker: Christian Seitz

1:00 p.m.

Bio-Techne

Interrogating complex tumors by spatial profiling in research and clinical applications

The RNAscope™ in situ hybridization (ISH) technology is a robust method to detect gene expression with spatial and morphological tissue context. This technology enables single-cell imaging to visualize and assess the gene expression of multiple cytokines, chemokines, immune cell markers, tumor and checkpoint markers within the tumor microenvironment (TME). To understand the cellular cross-talk within the TME, it is essential to simultaneous study target gene and protein expression. Combining RNAscope ISH with immunohistochemistry /immunofluorescence explores the natural complementarity of these techniques and provides a multiomic approach to understand complex spatial relationship among different cell types within the TME.

Speaker: Anushka Dikshit; Robert Monroe

3:00 p.m.

Genmab

Harnessing the Power of the Immune System Through Antibody Technologies

Non-classical antibody-based platforms represent the next generation of antibody targeted therapies and have been the core of our innovation powerhouse at Genmab. This presentation will focus on two antibody technologies developed following our "inspired by nature" philosophy – the DuoBody®bispecific platform, inspired by the functional characteristics of the natural Fab-arm exchange of IgG4, and HexaBody® platform- based on the discovery of complement activation by IgG hexamers assembled at the cell surface. We will discuss how we develop novel antibody products, whereby applying innovative translational research, we hope to solve the hurdles of antibody development and transform cancer therapy.

Speakers: **Janine Schuurman; Kate Sasser**

Tuesday, April 13, 2021

11:00 a.m.

NanoString

New Approaches for Cellular Therapies: Technology Symposium Featuring the GeoMx® Digital Spatial Profiler (DSP) and nCounter® CAR-T Characterization

As the field of cellular therapy advances, so does the need for innovative tools that improve performance and efficacy. NanoString's GeoMx® DSP and nCounter products are at the forefront of innovation. University of Pennsylvania collaborators will share new ways of spatially profiling CAR-T in lymphoma and solid tumors and molecular profiling of samples utilizing a customized CAR-T Characterization panel developed analysis of apheresis, CAR-T product and transgene inserts. Garvan Institute collaborators will present data exploring the ability to spatially profile TCR expression, with the potential to yield valuable insights on the localization and distribution of T-cell tumor populations.

Speakers: **Ryan J. Golden; Marco Ruella; Ghamdan Al-Eryani**

1:00 p.m.

BD Biosciences

The power of single-cell analysis with the BD FACSymphony™ A1 Cell Analyzer and BD FACSMelody™ 4-Way Cell Sorter

The BD FACSymphony™ A1 Flow Cytometer makes single-cell analysis more accessible—bringing technology from the high-end BD FACSymphony™ Platform to a benchtop instrument, delivering enhanced sensitivity, performance and a dedicated small particle detector for deeper insights. Meaningful insights also require downstream assessments of cells of interest. The BD FACSMelody™ Cell Sorter provides a personalized sorting solution by automating complex setups with easy-to-use software, allowing you to obtain precious cells on your own time. Sorting populations of interest for downstream assays, transcriptomic analysis or in vivo assessment, brings multifaceted views of your biological system with this BD solution workflow.

Speaker: **Karen Ersland**

3:00 p.m.

10x Genomics

Resolve cancer with single cell and spatial multiomics

The complexity of cancer biology poses challenging questions, and 10x Genomics provides powerful single cell and spatial multiomic solutions to transform the way we approach cancer, illuminating underlying molecular mechanisms and enabling deep characterization of cancer progression and therapeutic response and resistance.

Join us to hear from researchers leveraging single cell and spatial technologies to further understand patient responses to CD19 CAR T-cell therapy, discover the power of multimodal analysis for resolving the heterogeneity and immune composition of the tumor microenvironment, and explore our latest technological advancements, including spatial gene expression for FFPE tissue.

Speakers: **Abbey Cutchin; Jonathan Bibliowicz; Ansu Satpathy**

Wednesday, April 14, 2021

11:00 a.m.

AstraZeneca

The Orchestrated Immune Response: Dynamic Forces Guiding Cancer Immunity

Targeted immuno-oncology medicines have had a tremendous impact on cancer treatment, but some cancers remain impervious to immunotherapy and responses are unpredictable in many tumor types.

Here we debut a new framework for understanding the role of the immune system in cancer by characterizing the immune system as an ***active decision-maker.*** A coordinated set of decisions by innate and adaptive immune cells results in three distinct states: *Ignore*, *Attack*, or *Defend*. Scientists and researchers developing future immuno-oncology therapies should start with a clearer view of the cancer patient's underlying immune state to more successfully drive to the *Attack* state.

Speaker: Mark Cobbold

1:00 p.m.

Bionano Genomics

Optical Genome Mapping: Unrivaled Structural Variant Detection for Cancer Research and Precision Medicine

The heterogeneity and magnitude of genomics rearrangements in cancer makes it refractory to complete characterization by current technologies such as NGS. Optical genome mapping (OGM) uniquely addresses such complexity by imaging megabase-long DNA molecules at up to 1600x coverage to discover SVs unbiased, genome-wide down to 1% VAF.

We will show work on DNA replication, long-range methylation phasing, biomarker discovery, and identification of new classes of SVs and structural signatures for patient stratification in precision medicine. Finally, we will review studies from around the world showing the potential of OGM to modernize current standards of care to improve patient management.

Speakers: Ben Finlay; Yannick Delpu

3:00 p.m.

Adaptive Biotechnologies

Utilizing Immunosequencing in Cancer Research and Drug Discovery

Adaptive Biotechnologies' immunoSEQ® Technology is an end-to-end immunosequencing solution capable of profiling millions of B- and T-cell receptors at high throughput and providing a quantitative view into the immune repertoire. This presentation provides:

• An overview of the immunoSEQ Technology.
• Highlighting key use cases of the immunoSEQ Technology in oncology research.
• Applications in pre-clinical and clinical research settings.
• An overview of Adaptive's drug development capabilities, including identifying and characterizing viable therapeutic targets in solid tumors.

immunoSEQ is for Research Use Only. Not for use in diagnostic procedures..

Speakers: **Patrick Raber; Adria Carbo**

Thursday, April 15, 2021

11:00 a.m.

Visiopharm

Phenotyping in the tumor microenvironment

How much information can you extract from a multiplex image? What then?
Visiopharm's Phenotyping module is a powerful tool for analyzing multiplex images.
Join our Technical Specialist David Mason for a dive into multiplex analysis of the tumor microenvironment using data created with the Ultivue InSituPlex® technology. We will look at how you can use image data to interrogate the tumor immune landscape as well as the following topics:

- Tissue segmentation into areas of interest using single or multiple channels
- Unbiased phenotyping across a panel of cell probes
- Comparing analysis in different regions
- Customizing outputs to ask specific questions

Speakers: Dave Mason

1:00 p.m.

PerkinElmer

Scientific advancements in oncology research from in vitro to in vivo imaging

● Cancer-on-a-chip model platform to monitor cancer cell invasion and metastatic spread

In the first talk titled, "Cancer-on-a-chip platform to model tumor cell invasion and metastatic spread", Dr. Mumenthaler will cover the advancements of implementing organ-on-chip models using high content imaging and mass spectrometry-based metabolomics to improve the understanding of colorectal cancer progression to improve treatment efficacy.

Speaker: Shannon Mumenthaler

● In Vivo Imaging Mitochondrial Bioenergetics and Oxidative Stress in Lung Cancer

In the second talk titled, "In vivo imaging of mitochondrial bioenergetics and oxidative stress in lung cancer", Dr. Shackelford will cover the role of mitochondria as an essential regulator of cellular energy, metabolism and oxidative stress to identify phenotypes using in vivo imaging with bioluminescence and positron emission tomography to guide precise delivery of small molecule OXPHOS inhibitors in lung cancer.

Speaker: David B. Shackelford